3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
9
Thyroid Neoplasms
4
Thyroid Cancer, Papillary
4
Neoplasms
3
Multiple Myeloma
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma, Follicular
2
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Ovarian Neoplasms
1
Nonseminomatous germ cell tumor
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1
Melanoma
1
Lymphoproliferative Disorders
1
Leukemia, Hairy Cell
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Differentiated Thyroid Cancer (DTC)
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Adenoma, Oxyphilic
1
Interventions
trametinib
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
dabrafenib
×
Endocrine
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled